Mperia Therapeutics logo

Mperia Therapeutics

1 Follower


Mperia Therapeutics is spin-off company from AmorChem Fund 1, focusing on macrophage-driven inflammation via CD36 receptor immuno-metabolism. Lead candidates are CD36 receptor targetted cyclic peptides, showing clear efficacy in dry form of age-related macular degeneration (dry AMD), atherosclerosis and NASH models.

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.